SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-217063
Filing Date
2023-08-21
Accepted
2023-08-21 17:13:59
Documents
12
Period of Report
2023-08-16
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d544298d8k.htm   iXBRL 8-K 21906
  Complete submission text file 0001193125-23-217063.txt   142934

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vnda-20230816.xsd EX-101.SCH 2890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20230816_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20230816_pre.xml EX-101.PRE 11288
6 EXTRACTED XBRL INSTANCE DOCUMENT d544298d8k_htm.xml XML 3366
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 231189983
SIC: 2834 Pharmaceutical Preparations